Hidradenitis Suppurativa clinical trials at UCLA
1 research study open to eligible people
Showing trials for
Subcutaneous Sonelokimab Compared with Placebo in Adult Participants with Moderate to Severe Hidradenitis Suppurativa
open to eligible people ages 18 years and up
This is a study to evaluate the clinical efficacy and safety of sonelokimab administered subcutaneously compared with placebo in the treatment of adult participants with moderate to severe hidradenitis suppurativa. Participants will be randomized 2:1 to either sonelokimab or matching placebo up to Week 16.
Northridge, California and other locations
Our lead scientists for Hidradenitis Suppurativa research studies include April W. Armstrong, MD, MPH.
Last updated: